5250-39-5Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)OUIOFUWFRIANQPC-JKIFEVAISA-NFlucloxacillin is a penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain. It has a role as an antibacterial drug. It is a penicillin and a penicillin allergen. It is a conjugate acid of a flucloxacillin(1-).
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Antibiotics
Pharmaceuticals -> Used in Switzerland
Pharmaceuticals -> Anti infectives for systemic use -> Antibacterials for systemic use
3.2
2.58
Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antibacterial Agents; Penicillins
Access group antibiotics
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Flucloxacillin
DILI Positive
oral
DOI:10.1016/j.drudis.2019.09.022
J01CF05
J - Antiinfectives for systemic use
QJ - Antiinfectives for systemic use
QJ - Antiinfectives for systemic use
J01CF02
Flucloxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Flucloxacillin has <i>in vitro</i> activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Flucloxacillin results from the inhibition of cell wall synthesis and is mediated through flucloxacillin binding to penicillin binding proteins (PBPs). Flucloxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, flucloxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that flucloxacillin interferes with an autolysin inhibitor.
Hepatic.
Flucloxacillin has known human metabolites that include 6-[[3-(2-Chloro-6-fluorophenyl)-5-(hydroxymethyl)-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.
5250-39-5DTXSID8023056CHEMBL222645CHEBI:5098개요Chemically this is 3(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl penicillin; this differs from dicloxacillin only by the substitution of a fluorine for a chlorine atom (Sutherland et al., 1970). It comes as oral capsules of 250 and 500 mg, as a suspension of 25 and 50 mg/ml, and in an injectable formulation of 500 mg and 1 g.
용도Antibacterial.
일반 설명Flucloxacillin was synthesized by Beecham Research Laboratories in 1962 as a penicillinase-stable and orally active semisynthetic penicillin. It shows almost the same activity as dicloxacillin, and it has slightly higher serum and tissue concentrations than dicloxacillin. This drug has been used to treat pyoderma, sepsis, and postoperative infections as well as ear and nose, respiratory tract, and other infections caused by Staphylococcus and Streptococcus, including benzylpenicillin-resistant strains.
정의ChEBI: A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.